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Abstract
Chk1 is a serine/threonine protein kinase that is the effector of the G2 DNA damage checkpoint.
Chk1 homologs have a highly conserved N-terminal kinase domain, and a less conserved C-
terminal regulatory domain of ~200 residues. In response to a variety of genomic lesions, a number
of proteins collaborate to activate Chk1, which in turn ensures that the mitotic cyclin-dependent
kinase Cdc2 remains in an inactive state until DNA repair is completed. Chk1 activation requires
the phosphorylation of residues in the C-terminal domain, and this is catalyzed by the ATR protein
kinase. How phosphorylation of the C-terminal regulatory domain activates the N-terminal kinase
domain has not been elucidated, though some studies have suggested that this phosphorylation
relieves an inhibitory intramolecular interaction between the N- and C-termini. However, recent
studies in the fission yeast Schizosaccharomyces pombe have revealed that there is more to Chk1
regulation than this auto-inhibition model, and we review these findings and their implication to the
biology of this genome integrity determinant.
Review
A little history: control of entry into mitosis and the 
identification of chk1
The cell cycle is an orderly progression driven by the activ-
ities of the cyclin-dependent kinases (CDK) that control
the transitions from G1 in S-phase, and from G2 into
mitosis. The G2/M transition is particularly ancient in ori-
gin and is controlled by a universal mechanism common
to virtually all eukaryotes [1]. Cdc2 (also known as Cdk1)
is the mitotic CDK, and its activity is reliant upon binding
to the cyclically expressed A- and B-type cyclins. To ensure
that the transition from G2 into mitosis is a rapid switch,
Cdc2 molecules that bind to cyclin partners are rapidly
inactivated by inhibitory tyrosine phosphorylation on res-
idue 15 (Y15). This inhibitory phosphorylation is cata-
lyzed by the Wee1-family of kinases. During G2, Y15
phosphorylated Cdc2-Cyclin complexes accumulate, and
are maintained in this inactive state until conditions
appropriate for mitotic entry are completed. Given the
highly mechanical and irreversible nature of mitosis,
achieving appropriate cell mass, the completion of DNA
replication and the absence of genomic lesions are crucial
criteria that must be met for the cell to commit to mitotic
entry. Once these conditions are met, Cdc2 is rapidly acti-
vated by dephosphorylation of Y15, catalyzed by the
Cdc25-family of phosphatases [2]. This becomes a "point
of no return", and the cells are then committed to pass
through mitosis, where proteolysis of the cyclins resets the
system for the subsequent cell cycle [3].
To ensure cells do not enter mitosis prematurely, check-
points overlay the core cell cycle machinery to ultimately
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control Cdc2 activation. DNA damage in S-phase or G2
delays mitotic entry, and the pioneering work of Weinert
and Hartwell in Saccharomyces cerevisiae discovered a
number of radiation sensitive mutants (the RAD genes)
that were defective in mounting a checkpoint-mediated
delay to mitosis [4]. Work in S. pombe by a number of lab-
oratories, most notably by Tony Carr and colleagues, also
identified checkpoint genes among radiation sensitive
mutants [5-9]. One of these, rad27 [6], was the same gene
as chk1, a gene that was previously identified by Nancy
Walworth, and shown to encode a serine/threonine pro-
tein kinase required for DNA damage checkpoint arrest
[8].
Homologs of this kinase have subsequently been identi-
fied in all eukaryotes. They share a highly conserved N-ter-
minal kinase domain, and a C-terminal domain that
while not well conserved, is ~200 residues in all species,
contains two regions of conserved sequences, and has
therefore been described as a regulatory domain (Figure
1). How Chk1 is regulated has turned out to be a remark-
ably complex series of events, involving many upstream
elements, though most of these have now been identified.
What is still lacking is an understanding of the precise
molecular mechanisms of Chk1 activation. Here, we
review recent progress focusing on Chk1 function and reg-
ulation in S. pombe, which has continued to provide an
excellent model for studying this pathway and cell cycle
regulation relevant to all eukaryotes.
Signaling upstream and downstream of Chk1
In the initial study of Chk1, Walworth showed that its
overexpression alone caused a G2 cell cycle arrest, and this
did not require any of the other checkpoint rad genes, sug-
gesting it was a downstream element in a putative signal-
ing cascade [8]. As Y15 phosphorylation of Cdc2 is so
critical to control mitotic entry, it was perhaps not surpris-
ing that this was the mechanism by which Chk1 delays
cells in G2 [10,11]. To achieve this, Chk1 phosphorylates
Wee1, stabilizing the protein to increase cellular pools of
Wee1 [12], and also Cdc25, where phosphorylation is
inhibitory over catalytic activity and also affects sub-cellu-
lar localization [13,14]. Cells that lack both Wee1 and
Cdc25 are viable, and still utilize the regulated abundance
of cyclins to control cell cycle progression. Such cells,
however, lack a checkpoint response to DNA damage, and
also fail to respond to Chk1 overexpression [12], suggest-
ing these molecules are the key substrates for Chk1, at
least in S. pombe.
The first clue to Chk1 activation came from the observa-
tion that DNA damage led to a phosphorylation of Chk1
that was dependent on all the upstream checkpoint genes
[15]. From several studies in diverse experimental sys-
tems, the events leading to Chk1 phosphorylation have
been delineated, and extensively reviewed [16-19].
Briefly, primary lesions are converted into single stranded
DNA (ssDNA), which is rapidly coated by the ssDNA-
binding protein Replication Protein A (RPA). This acts as
a landing pad for Rad26 (ATRIP in humans) [20], together
with its associated kinase, Rad3 (ATR in humans). Inde-
pendently, the PCNA-related 9-1-1 complex, comprised of
Rad9, Rad1 and Hus1, is loaded onto these sites by a var-
iant of Replication Factor C (RFC), in which the large sub-
unit is replaced by Rad17 [21]. Two BRCT-domain medi-
ator proteins, Cut5 and Crb2 (TopBP1 ad 53BP1 in
humans), are also recruited to the complexes, and finally
Chk1 is recruited into the checkpoint complex via an
interaction with Crb2 [22]. This brings Chk1 into proxim-
ity to Rad3, which then phosphorylates Chk1 in Serine
345 (S345) in the C-terminal regulatory domain [23,24].
Human Chk1 contains an additional phosphorylation
site at S317 [25,26], but the analogous site in S. pombe
Chk1 (T323) is not required for Chk1 activation [24].
S. pombe Chk1 domain structure Figure 1
S. pombe Chk1 domain structure. Chk1 has an N-terminal kinase domain (blue) and a C-terminal regulatory domain (yel-
low). Regions required for 14-3-3 interaction and nuclear localization [42] are indicated below the schematic. The position of 
S345 (orange), the site of activating phosphorylation is shown, as are the two regions of the C-terminal domain conserved 
across species that have been analyzed by mutagenesis [45]. These are "region 1" (green; residues 394–400, RLTRFYS in S. 
pombe, RMTRFYS in humans), and "region 2" (red; residues 468–477, GDPLEWRKFF in S. pombe, GDPLEWRKFY in humans).
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Activation and inactivation of Chk1
Phosphorylation of S345 activates Chk1 kinase activity
~5–10-fold over a basal activity that is clearly measurable
[27-29]. Whether this basal activity plays a significant role
in regulating cell cycle progression has not been rigor-
ously tested, but a S345A mutant grossly resembles a null
allele of chk1 (chk1Δ) suggesting any effect is minor com-
pared to the induced activity [24]. Curiously, acidic sub-
stitutions at S345 are not phospho-mimetic, and indeed
inactivate Chk1 and phenocopy S345A (and chk1Δ) [24].
Chk1 activation is extremely rapid, and the magnitude of
activation is saturated at relatively low levels of DNA dam-
age. However, the duration of the checkpoint arrest is
clearly dose-dependent, suggesting that Chk1 exists in
either an "on or off" state [27]. The precise signal to inac-
tivate Chk1 is not known, but thought to derive from
completion of DNA repair. Inactivation of Chk1 during a
DNA damage induced checkpoint arrest is sufficient to
send cells immediately into mitosis [27]. In S. pombe, one
of two type 1 Protein Serine/Threonine Phosphatases
(PP1), Dis2, is both necessary and sufficient to dephos-
phorylate S345 and inactivate Chk1 [28,30]. While PP1
phosphatases have also been shown to inactivate Chk1 in
human cells [31], other phosphatases and even other
mechanisms have been proposed [31-33], and as seen in
S. pombe, up-regulating S345 dephosphorylation also
abrogates a checkpoint arrest.
Remarkably, although Chk1 is and must be inactivated for
cells to recover from the checkpoint arrest, Chk1 is reacti-
vated in the following cell cycle without apparent DNA
damage, and yet the cells cycle normally [27,28]. This
apparent paradox may be explained if DNA damage inac-
tivates a Chk1 antagonist, but in the following cell cycle
such an antagonist is active and negates the activated
Chk1. Candidate antagonists in this scenario are the Cdr
kinases Cdr1 and Cdr2. Like Chk1, Cdr kinases phospho-
rylate Wee1, but unlike the activation of Wee1 by Chk1,
Cdr kinases are Wee1 inhibitors [34-38]. The inactivation
of both of these kinases renders cells hypersensitive to
Chk1 overexpression, and conversely the overexpression
of Cdr1 renders cells checkpoint defective and insensitive
to Chk1 signaling [39]. Whether Cdr kinase homologs are
Chk1 antagonists in other systems, and whether they are
themselves regulated by DNA damage remains to be
determined.
An auto-inhibitory model to control Chk1 function
Clearly S345 must be phosphorylated for Chk1 to be
active, but how does this modification to the C-terminal
domain activate the N-terminal kinase domain? The struc-
ture of the catalytic domain (but not the full-length pro-
tein) of human Chk1 has been solved, and it is in an open
conformation; that is, it does not require modification to
adopt the fold of an active kinase [40]. Moreover, the
kinase activity of the isolated catalytic domain is substan-
tially elevated over the full-length molecule, which sug-
gested that the C-terminal domain might be auto-
inhibitory through an interaction with the catalytic
domain, and perhaps such an interaction is disrupted by
phosphorylation (Figure 2).
Auto-inhibition model of Chk1 regulation Figure 2
Auto-inhibition model of Chk1 regulation. A. Using the same color scheme as in Figure 1, in its inactive (unphosphor-
ylated) state, the C-terminal domain physically interacts with the kinase domain, precluding it from phosphorylating substrates. 
B. This intramolecular interaction is blocked by S345 phosphorylation, opening the molecule to uncover the kinase domain.
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This model has been tested using ectopically expressed
fragments of Chk1 in Xenopus oocyte extracts, and indeed
this study showed that separately expressed N- and C-ter-
minal domains physically interact [41]. Consistent with
the model of activation by phosphorylation, phospho-
mimetic substitutions at the ATR phosphorylation sites,
or treatment with aphidicolin (a DNA polymerase alpha
inhibitor that activates Chk1), disrupted the interaction
between separately expressed N- and C-terminal domains.
However, in the context of full-length Chk1, acidic substi-
tutions did not activate Chk1's kinase activity, and expres-
sion of the C-terminal domain did not activate or interact
with the full-length protein [41]. Further, unpublished
work from our laboratory using similar experiments over-
expressing fragments of Chk1 in S. pombe have failed to
show N- and C-terminal domain interactions, and we
have observed no effect of overexpression of the C-termi-
nal domain on the function of the endogenous full-length
protein. Therefore, while auto-inhibition by N- and C-ter-
minal domain interaction may be a component of Chk1
regulation, it appears the mechanism of activation may be
more complex.
Chk1 has positive regulatory elements in the C-terminal 
domain
From a series of studies over the last 16 years from several
groups, 45 independent mutant alleles of S. pombe chk1
have been characterized (Table 1) [6,8,9,24,27,42-46].
These have come from classical screens, site-directed
mutagenesis and simple truncations. For the later, given
the data with human Chk1 in vitro [40], and with Xenopus
Chk1 in oocyte extracts [41], a prediction would be that C-
terminal truncations should activate Chk1 and cause a G2
cell cycle arrest. However, a series of truncations con-
structed by our laboratory and spanning the entire C-ter-
minal domain to just the final 11 residues completely
inactivate the protein in terms of its ability to rescue the
functional defects of a chk1Δ allele [45]. The C-terminal
domain includes a nuclear localization sequence and a
14-3-3-interaction domain [42], but truncations that
leave these intact are also non-functional. Therefore, the
C-terminal domain must contain additional sequences
necessary for function in vivo.
A number of non-functional alleles are mutations in con-
served residues within the kinase domain, and can be eas-
ily explained by a reduction or lack of kinase activity.
However, there are also many non-functional mutant alle-
les that are single amino acid substitutions in the C-termi-
nal domain. Some of these are in the two highly
conserved regions, and most were generated by site-spe-
cific mutagenesis based on homology between human
and  S. pombe Chk1. However, several loss-of-function
alleles of S. pombe chk1 are in non-conserved regions of
the C-terminal domain, suggesting that they alter struc-
Table 1: Mutant alleles of S. pombe chk1
Allele Mutation Reference
chk1Δ Null [6,8]
chk1-T15 ND1 [6]
chk1-1 E92D [46]
chk1–2 I484T [46]
chk1-NC18 ND [9]
chk1-NC73 ND [9]
chk1-NE3 ND [9]
-K 3 8 A [ 4 4 ]
- G108S [44]
- F118L, S311F [44]
- N142D [44]
- L144P [44]
- D155G [44]
- D155A [44]
- D155E2 [44]
- D363G, D469G [44]
- S345A [23,24]
- S345D [24]
chk1-ts1 E472D3,7 [27]
chk1-ts2 E111R4 [27]
chk1-ts3 L151S4 [27]
chk1-ts4 I389S4 [27]
chk1-ts5 ΔI4844 [27]
- L291A5 [42]
- L295A5 [42]
- L299A5 [42]
- L303A5 [42]Cell Division 2009, 4:8 http://www.celldiv.com/content/4/1/8
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ture to a point that disrupts function. Unfortunately, no
structural data for the C-terminal domain has been
reported on which these mutants can be mapped. Never-
theless, these non-functional C-terminal point mutants
support the interpretation of the truncation mutations;
that is, regardless of whether it is inhibitory or not, the C-
terminal domain is critical for Chk1 function in vivo.
Activating mutations in the C-terminal domain
Our laboratory has also isolated activating mutations in
the conserved regions of the C-terminal domain [45]. The
analysis of these alleles supports the auto-inhibitory
model, functionally separating them from the inactivating
mutations within the very same domains. Modest overex-
pression of Chk1 from a heterologous attenuated nmt1
promoter has no affect on cell cycle progression. How-
ever, the expression of substitutions at two conserved res-
idues, R394A and E472D, from the same attenuated nmt1
promoter causes a lethal G2 cell cycle arrest. Each of the
activating mutations in the C-terminal domain required
kinase activity to elicit a cell cycle arrest, but all were inde-
pendent of S345 phosphorylation. The simplest interpre-
tation is that these activating C-terminal mutations are
having the same net biochemical effect on Chk1 as does
S345 phosphorylation.
Remarkably, the E472D mutation corresponded to a tem-
perature-sensitive loss-of-function allele (chk1-ts1) we had
previously isolated [27]. When expressed from its own
promoter, Chk1-E472D is a less stable protein, suggesting
that while this mutation imparts an activated conforma-
tion, this is also destabilizing and the protein is more rap-
idly degraded.
Several second site mutations within Chk1 that suppress
the gain-of-function conferred by the E472D mutation,
but result in a fully functional protein were selected [45].
One of these suppressor mutations, an in frame deletion
of residues 359–361 (Δ359–61), is itself a gain-of-func-
tion mutant when mildly overexpressed, and like E472D,
confers a temperature sensitive loss-of-function when
expressed from the endogenous locus. Thus, Δ359–61 and
E472D show mutual suppression, where the combination
of two activating mutations in the same protein likely
confers a more wildtype conformation.
Several of the other E472D suppressors clustered to
regions in the catalytic domain. When the positions of
these residues are mapped onto the crystal structure of the
human enzyme, each cluster mapped onto loops on either
side of the catalytic cleft on the face of the protein that
interacts with substrate. We speculate that, when Chk1 is
in an inactive conformation, these regions within the cat-
alytic domain interact with the C-terminal domain, and
that this interaction occludes the active site. The E472D
mutation may destabilize this interaction, but the sup-
pressor mutants restore the interaction to return the mol-
ecule to a wildtype conformation (Figure 3).
Further physical analyses will be required to test this
model. The end result is that this model is essentially a
slightly refined version of the auto-inhibition model pro-
posed by Sagata and colleagues, and as such, also does not
take into account why the C-terminal domain is essential
for function in vivo. However, the collection of mutants of
defined function might enable us to separate the negative
and positive regulatory elements within this domain, and
chk1–4A K377A, R378A, K381A, K382A6 [42]
-D 3 6 3 G [ 4 3 ]
-D 4 6 9 G [ 4 3 ]
- Δ280–496 [45]
- Δ327–496 [45]
- Δ393–496 [45]
- Δ444–496 [45]
- Δ467–496 [45]
- Δ486–496 [45]
- Δ359–3613,7 [45]
- R394A7 [45]
- R394A, R397A [45]
- F398A, Y399A [45]
- Δ394–400 [45]
-E 4 7 2 A [ 4 5 ]
- ΔE472 [45]
- ΔF477 [45]
- Δ473–477 [45]
- G468A, D469A, P470A, E472A [45]
Notes: 1Not determined; 2dominant-negative when overexpressed; 
3temperature sensitive loss-of-function; 4temperature sensitive loss-
of-function when expressed from a multi-copy plasmid, but non-
functional when expressed from the chk1 locus; 5disrupts 14-3-3 
binding; 6blocks nuclear localization; 7gain-of-function when expressed 
from the attenuated nmt1 promoter.
Table 1: Mutant alleles of S. pombe chk1 (Continued)Cell Division 2009, 4:8 http://www.celldiv.com/content/4/1/8
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move towards a detailed view of the mechanism of activa-
tion (and inactivation) for Chk1.
Conclusion
Chk1 was first identified 16 years ago, and in the interim
we have learned much about the events leading to its acti-
vating phosphorylation. At a mechanistic level, we have
learned comparatively little regarding how this phospho-
rylation actually elevates Chk1 kinase activity. Because the
G2 checkpoint appears to be required for tumor cell via-
bility, there has been significant interest in inhibiting
Chk1 as a means to treat cancer, though most of these
studies have relied on ATP analogs [47]. Determining
more precise mechanisms of Chk1 activation is thus not
only important for the biology of this highly conserved
pathway, but may also have profound implications in the
design of Chk1-based anti-cancer therapeutics.
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